knowledge -WSS

knowledge

author：fashion 2025-10-01 00:07:09 - browse：8736

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why Medicare shouldn’t cover every FDA

hotspot

WSS

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Merck, Johnson & Johnson CEOs will testify on high drug prices

What to do when lifesaving products contribute to climate change

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

U.K. Biobank has 500,000 peoples' genome sequences available

Organ aging and disease risk measured by new blood test

knowledge

knowledge

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

10 reasons why health care startups fail

Dobbs anniversary: the lost opportunity of abortion as health care

Despite FDA concern, risk that CAR

Affirmative action in medical school literally saved lives

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Syphilis numbers in the United States reach record heights

Peter Hotez and the public health issue of online harassment

The EPA's new lead rule: How one expert crunched the numbers

entertainment

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Health Care Service Corp to buy Cigna Medicare Advantage plans

Takeda, Janssen join wearable maker to measure scratching

Boston competes with Raleigh

Rep. Raul Ruiz on the physician shortage and more

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

focus

hotspot

hotspot

hotspot